Physician profile
Terry Tack
NPI 1568177749
$2,469.71
in general payments reported to CMS, 2019-2025
20 companies · $925 in 2025
The $925 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $470 · 2024: $1,075 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $356.09 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $340.88 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $233.47 | 2024-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $228.24 | 2023-2025 | |
| Lundbeck LLC | $226.05 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $213.22 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $173.38 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $128.34 | 2023-2025 | Spravato |
| Bausch Health US, LLC | $122.10 | 2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $110.31 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $54.29 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $50.81 | 2024-2025 | Austedo Xr, Uzedy |
| Collegium Pharmaceutical, INC. | $46.90 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $41.28 | 2023 | Methylphenidate Hydrochloride |
| Idorsia Pharmaceuticals US INC | $38.99 | 2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.76 | 2023-2024 | Caplyta |
| Vertical Pharmaceuticals, LLC | $23.16 | 2024 | Relexxii |
| Neurocrine Biosciences, INC. | $21.74 | 2025 | |
| Ironshore Pharmaceuticals INC. | $18.68 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.02 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Tack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.